Picture loading failed.

Anti-LAG3 therapeutic antibody (Pre-made Fianlimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Fianlimab (previously REGN 3767) is an anti-lymphocyte-activation gene 3 (LAG3) monoclonal antibody, being developed by Regeneron Pharmaceuticals, for the treatment of solid tumours and haematological malignancies.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-210-1mg 1mg 3090
GMP-Bios-ab-210-10mg 10mg 21890
GMP-Bios-ab-210-100mg 100mg 148000
GMP-Bios-ab-210-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-LAG3 therapeutic antibody (Pre-made Fianlimab biosimilar,Whole mAb)
INN Name Fianlimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions ActiveCancer
Conditions Discontinuedna
Development Techna